# Reasoning Log: In the InfoGripe bulletin published on or immediately before June 25, 2026, which respiratory virus will be the single most prevalent among positive SRAG cases nationally over the most recent 4-week window?

*Generated: 2026-06-15T02:53:08.557432+00:00*


## 💭 Thinking

Let me analyze this forecasting question about which respiratory virus will be most prevalent in Brazil's InfoGripe bulletin published on or immediately before June 25, 2026.

Key facts from the question:
1. The most recent bulletin (June 11, 2026, SE 22) showed: Rhinovirus 33.2%, Influenza A 20.5%, VSR 8.5%, Influenza B 2.6%
2. Earlier in 2026, rhinovirus led by ~45%, but the gap with influenza A has been narrowing
3. Seasonally: RSV peaks autumn/early winter, Influenza A rises June-August, Rhinovirus circulates year-round
4. The target bulletin will likely be from June 18 or June 25, so I'm looking at a very short timeframe—just one or two weeks from the most recent data

## 🔧 Tool: mcp__metaculus__get_metaculus_questions


```json
{
  "post_id_list": [
    44052
  ]
}
```

### 📋 Result

```
{"post_id": 44052, "title": "In the InfoGripe bulletin published on or immediately before June 25, 2026, which respiratory virus will be the single most prevalent among positive SRAG cases nationally
over the most recent 4-week window?", "type": "multiple_choice", "url": "https://www.metaculus.com/questions/44052", "background_info": "InfoGripe is the weekly severe acute respiratory illness
(SRAG/SARI) surveillance bulletin produced by Fiocruz (Icict), based on Brazil's SIVEP-Gripe system. Each bulletin reports, among laboratory-positive SRAG cases over the most recent four
epidemiological weeks (SEs), the percentage distribution across the main respiratory viruses: rhinovirus (rinov\u00edrus), influenza A, influenza B, respiratory syncytial virus (VSR/RSV), and SARS-
CoV-2.\n\nBulletins are published weekly (typically Thursdays) and summarized on the Ag\u00eancia Fiocruz de Not\u00edcias page at https://agencia.fiocruz.br/infogripe, each identified by its
epidemiological week (Semana Epidemiol\u00f3gica, SE). The bulletin published June 11, 2026 covered SE 22 (May 31\u2013June 6, 2026). Among positive cases over the most recent 4 weeks it reported
approximately: rhinovirus 33.2%, influenza A 20.5%, VSR 8.5%, influenza B 2.6%, plus SARS-CoV-2 and others. Earlier in 2026 rhinovirus led by a wider margin (around 45%), with the
rhinovirus\u2013influenza A gap narrowing over recent months.\n\nSeasonally in Brazil, RSV tends to peak in autumn/early winter while influenza A typically rises through deep winter
(June\u2013August). Rhinovirus circulates year-round and has recently been the largest single category. As of mid-June 2026, rhinovirus leads, influenza A is the main rising virus among
adolescents/adults/elderly, and VSR predominates among young children but has declined sharply from earlier in the year.\n\n`{\"format\": \"llm_question\", \"info\": {\"rating\": {\"quality\": 3,
\"ambiguity\": 3, \"resolvability\": 4, \"passes\": true}}}`", "resolution_criteria": "This question resolves based on the InfoGripe bulletin published on or immediately before June 25, 2026 (i.e.,
the most recent bulletin dated on or before that date), as reported on the Ag\u00eancia Fiocruz de Not\u00edcias InfoGripe page (https://agencia.fiocruz.br/infogripe). It resolves to the single
respiratory virus with the highest reported prevalence (percentage) among laboratory-positive SRAG cases over the most recent four epidemiological weeks (\"\u00faltimas 4 semanas\" /
\"preval\u00eancia entre casos positivos\"). Resolution maps the leading virus to one of: \"Rhinovirus (Rinov\u00edrus)\", \"Influenza A\", \"VSR (RSV)\", or \"Any other virus (Influenza B, SARS-
CoV-2, or other)\". Example: if rhinovirus is reported at 31% and is the highest of any single virus, this resolves \"Rhinovirus (Rinov\u00edrus)\".", "fine_print": "If the bulletin reports influenza
only as a combined \"Influenza (A+B)\" figure without a separate Influenza A value, use the Influenza A value if separately reported; the combined figure is not used. \"Most recent four
epidemiological weeks\" refers to the rolling 4-week window the bulletin uses for its \"casos positivos\" virus distribution, not the cumulative annual figures. If two viruses are tied for the highest
prevalence, the question resolves to \"Any other virus (Influenza B, SARS-CoV-2, or other)\" only if neither tied virus is among the three named options; otherwise it resolves to whichever tied named
virus the bulletin lists first. If the InfoGripe page is unavailable, the corresponding bulletin PDF (Resumo_InfoGripe_2026_XX) or reporting by credible sources
(https://www.metaculus.com/faq/#definitions) may be used. If no bulletin covering data through at least SE 24 (week ending June 20, 2026) is published on or before June 25, 2026, the most recent
available 2026 bulletin as of June 25, 2026 is used.", "num_forecasters": 0, "community_prediction": null, "options": ["Rhinovirus (Rinov\u00edrus)", "Influenza A", "VSR (RSV)", "Any other virus
(Influenza B, SARS-CoV-2, or other)"]}
```

## 🔧 Tool: mcp__research__research


```json
{
  "questions": [
    {
      "query": "InfoGripe Fiocruz bulletin June 2026 respiratory virus prevalence SRAG rhinovirus influenza A",
      "ttl": "6h"
    },
    {
      "query": "Brazil respiratory virus seasonality influenza A rhinovirus transition winter June July historical pattern InfoGripe",
      "ttl": "3d"
    }
  ]
}
```

### 📋 Result

```
{"results": [{"query": "InfoGripe Fiocruz bulletin June 2026 respiratory virus prevalence SRAG rhinovirus influenza A", "entry": {"slug": "infogripe-fiocruz-bulletin-june-2026-respiratory-v-fa5773be",
"query": "InfoGripe Fiocruz bulletin June 2026 respiratory virus prevalence SRAG rhinovirus influenza A", "answer": "I now have comprehensive data from three consecutive InfoGripe bulletins (SE 20,
21, and 22). Let me compile the complete research report.\n\n---\n\n# InfoGripe Fiocruz Bulletin \u2013 June 2026: Respiratory Virus Prevalence (SRAG, Rhinovirus, Influenza A)\n\n## Overview\n\nThe
Fiocruz InfoGripe surveillance system has published three bulletins in late May\u2013June 2026 covering Epidemiological Weeks (SE) 20\u201322 (May 17 \u2013 June 6, 2026). All three bulletins document
a sustained nationwide increase in Severe Acute Respiratory Infection (SRAG) hospitalizations in Brazil, driven primarily by **respiratory syncytial virus (RSV/VSR)**, **influenza A**, and
**rhinovirus**. COVID-19 (SARS-CoV-2) remains at low levels.\n\n---\n\n## Most Recent Bulletin: SE 22 (Published June 11, 2026)\n\n**Reference period:** May 31 \u2013 June 6, 2026\n\n### Virus
Prevalence Among Positive SRAG Cases (Last 4 Epidemiological Weeks)\n| Virus | Cases (%) | Deaths (%) |\n|---|---|---|\n| RSV (VSR) | **49.6%** | 17.0% |\n| Rhinovirus | **24.5%** | 18.4% |\n|
Influenza A | **20.7%** | **46.5%** |\n| Influenza B | 5.7% | 9.9% |\n| SARS-CoV-2 (COVID-19) | 2.0% | 6.8% |\n\n### Year-to-Date 2026 (Cumulative) Virus Prevalence Among Positive SRAG Cases\n| Virus
| Cases (%) | Deaths (%) |\n|---|---|---|\n| Rhinovirus | **32.5%** | 20.4% |\n| RSV (VSR) | **33.1%** | 9.1% |\n| Influenza A | **24.4%** | **41.9%** |\n| SARS-CoV-2 (COVID-19) | 5.7% | 21.0% |\n|
Influenza B | 3.1% | 4.9% |\n\n### SRAG Case and Death Totals (YTD 2026, as of SE 22)\n- **82,544** SRAG cases notified\n- **40,259 (48.8%)** tested positive for a respiratory virus\n- **3,591** SRAG
deaths\n- **1,641 (45.7%)** deaths tested positive for a respiratory virus\n\n### Geographic Distribution (SE 22)\n- **11 of 27 states** at alert/risk/high-risk level with growth trend: Acre, Alagoas,
Amap\u00e1, Paran\u00e1, Par\u00e1, Rio Grande do Norte, Rio Grande do Sul, Roraima, Santa Catarina, Sergipe, and S\u00e3o Paulo.\n- **12 additional states** at alert/risk/high-risk but with
stabilizing or declining trends: Amazonas, Bahia, Cear\u00e1, Distrito Federal, Esp\u00edrito Santo, Goi\u00e1s, Maranh\u00e3o, Mato Grosso, Mato Grosso do Sul, Minas Gerais, Para\u00edba, and Rio de
Janeiro.\n- **10 of 27 state capitals** at alert/risk/high-risk with growth signal.\n\n### Key Trends by Virus (SE 22)\n- **RSV**: Continues increasing in most states in Northeast (AL, BA, CE, MA, PI,
RN, SE), Southeast (MG, RJ, SP), and South (PR, SC, RS) regions.\n- **Influenza A**: Continues increasing throughout the entire South region, plus Roraima and Rio Grande do Norte.\n- **Influenza B**:
Increasing especially in S\u00e3o Paulo, Paran\u00e1, and Mato Grosso do Sul.\n- **Rhinovirus**: Predominant among children/adolescents aged 5\u201314 years.\n- **COVID-19**: Remains at low incidence
nationwide.\n\n---\n\n## Prior Bulletin: SE 21 (Published June 3, 2026)\n\n**Reference period:** May 24\u201330, 2026\n\n### Virus Prevalence Among Positive Cases (Last 4 EW)\n| Virus | Cases (%) |
Deaths (%) |\n|---|---|---|\n| RSV (VSR) | 48.5% | 16.6% |\n| Rhinovirus | 24.3% | 16.9% |\n| Influenza A | 21.9% | 49.0% |\n| Influenza B | 5.1% | 8.2% |\n| SARS-CoV-2 | 2.1% | 9.0% |\n\n### YTD 2026
Totals (as of SE 21)\n- **77,153** SRAG cases notified\n- **37,153 (48.2%)** positive for a respiratory virus\n- YTD positives: Influenza A 25%, Influenza B 2.9%, RSV 31.6%, Rhinovirus 33.1%, SARS-
CoV-2 6%\n- **18 of 27 states** with growth trend\n\n---\n\n## Prior Bulletin: SE 20 (Published May 28, 2026)\n\n**Reference period:** May 17\u201323, 2026\n\n### Virus Prevalence Among Positive Cases
(Last 4 EW)\n| Virus | Cases (%) | Deaths (%) |\n|---|---|---|\n| RSV (VSR) | 47.6% | 13.4% |\n| Rhinovirus | 23.9% | 17.2% |\n| Influenza A | 22.4% | 51.2% |\n| Influenza B | 4.7% | 7.2% |\n| SARS-
CoV-2 | 2.3% | 9.6% |\n\n### YTD 2026 Totals (as of SE 20)\n- **70,211** SRAG cases notified\n- **33,245 (47.4%)** positive\n- YTD: Influenza A 25.4%, Influenza B 2.6%, RSV 29.7%, Rhinovirus 33.9%,
SARS-CoV-2 6.4%\n- **20 of 27 states** with growth trend; all states except Rond\u00f4nia at alert/risk/high-risk levels\n\n---\n\n## Trend Analysis (SE 20 \u2192 SE 22)\n\n### Weekly Virus Prevalence
(Last 4 EW Window) Trajectory\n| Virus | SE 20 | SE 21 | SE 22 | Direction |\n|---|---|---|---|---|\n| RSV | 47.6% | 48.5% | **49.6%** | \u2191 Rising |\n| Rhinovirus | 23.9% | 24.3% | **24.5%** |
\u2191 Slightly rising |\n| Influenza A | 22.4% | 21.9% | **20.7%** | \u2193 Declining as share |\n| Influenza B | 4.7% | 5.1% | **5.7%** | \u2191 Rising |\n| SARS-CoV-2 | 2.3% | 2.1% | **2.0%** |
\u2193 Declining |\n\n### Case Volume Trajectory\n| Metric | SE 20 | SE 21 | SE 22 | Weekly growth |\n|---|---|---|---|---|\n| Total SRAG cases (YTD) | 70,211 | 77,153 | 82,544 |
~5,400\u20137,000/week |\n| Positive cases (YTD) | 33,245 | 37,153 | 40,259 | ~3,100\u20133,900/week |\n| Positivity rate | 47.4% | 48.2% | 48.8% | \u2191 Increasing |\n| SRAG deaths (YTD) | \u2014 |
\u2014 | 3,591 | \u2014 |\n\n### Age-Specific Patterns\n- **Children <2 years**: SRAG driven primarily by **RSV**; influenza A incidence also high.\n- **Children/adolescents 5\u201314**: Driven
primarily by **rhinovirus**.\n- **Young adults, adults**: Influenza A dominant.\n- **Elderly (65+)**: Highest mortality, predominantly from **influenza A** (41.9\u201346.5% of deaths among
positives).\n- **COVID-19**: Low incidence across all age groups; growing only in Cear\u00e1, Maranh\u00e3o, and Par\u00e1.\n\n---\n\n## Key Takeaways\n\n1. **RSV is the dominant virus** in recent
weeks (~50% of positive cases), driving the SRAG surge especially in young children.\n2. **Rhinovirus** remains the second most prevalent virus in recent weeks (~24.5%) and is the leading virus
**year-to-date** (~32.5% cumulative), predominantly affecting ages 5\u201314.\n3. **Influenza A** is the **leading cause of SRAG deaths** (41.9\u201346.5% of positive deaths), despite being third in
case prevalence (~20.7% recent, ~24.4% YTD).\n4. **Influenza B** is rising (5.7% recent), especially in S\u00e3o Paulo, Paran\u00e1, and Mato Grosso do Sul.\n5. **COVID-19 remains at very low levels**
(~2% of recent positive cases), the lowest of all five monitored viruses.\n6. **All or nearly all Brazilian states** are at elevated SRAG alert levels, with 11\u201320 states showing active growth
trends depending on the week.\n7. Case volume is substantial: over **82,500 SRAG cases** and **3,591 deaths** YTD 2026 as of SE 22.", "sources": [{"url": "https://agencia.fiocruz.br/infogripe-cresce-
numero-de-hospitalizacoes-por-vsr-e-influenza-e-b", "title": "InfoGripe: cresce n\u00famero de hospitaliza\u00e7\u00f5es por VSR e influenza A e B (SE 22)", "domain": "agencia.fiocruz.br",
"accessed_at": "2026-06-15T00:00:00Z", "snippet": "Published June 11, 2026. Covers Epidemiological Week 22. Reports 82,544 SRAG cases YTD, 49.6% RSV, 24.5% rhinovirus, 20.7% influenza A among recent
positives."}, {"url": "https://agencia.fiocruz.br/infogripe-numero-de-casos-de-srag-mantem-crescimento-no-pais", "title": "InfoGripe: n\u00famero de casos de SRAG mant\u00e9m crescimento no pa\u00eds
(SE 21)", "domain": "agencia.fiocruz.br", "accessed_at": "2026-06-15T00:00:00Z", "snippet": "Published June 3, 2026. Covers Epidemiological Week 21. Reports 77,153 SRAG cases YTD, 48.5% RSV, 24.3%
rhinovirus, 21.9% influenza A among recent positives."}, {"url": "https://agencia.fiocruz.br/infogripe-numero-de-casos-de-srag-continua-aumentando-em-todas-faixas-etarias", "title": "InfoGripe:
n\u00famero de casos de SRAG continua aumentando em todas as faixas et\u00e1rias (SE 20)", "domain": "agencia.fiocruz.br", "accessed_at": "2026-06-15T00:00:00Z", "snippet": "Published May 28, 2026.
Covers Epidemiological Week 20. Reports 70,211 SRAG cases YTD, 47.6% RSV, 23.9% rhinovirus, 22.4% influenza A among recent positives."}], "key_facts": ["The most recent InfoGripe bulletin (published
June 11, 2026) covers Epidemiological Week 22 (May 31\u2013June 6, 2026) and reports rising SRAG hospitalizations nationwide driven by RSV, influenza A, and rhinovirus.", "RSV (VSR) is the dominant
virus in recent weeks at 49.6% of positive SRAG cases (last 4 epidemiological weeks as of SE 22), up from 47.6% at SE 20.", "Rhinovirus is the second most prevalent virus in recent weeks at 24.5% of
positive cases, and leads year-to-date at 32.5% cumulatively. It predominantly affects children and adolescents aged 5\u201314.", "Influenza A accounts for 20.7% of recent positive SRAG cases but is
the leading cause of SRAG deaths at 46.5% of positive deaths in the last 4 epidemiological weeks.", "Influenza B is rising, reaching 5.7% of recent positive cases, especially in S\u00e3o Paulo,
Paran\u00e1, and Mato Grosso do Sul.", "COVID-19 (SARS-CoV-2) is at very low levels: 2.0% of recent positive SRAG cases and 5.7% year-to-date.", "As of SE 22, 82,544 SRAG cases have been notified in
2026, with 40,259 (48.8%) testing positive for a respiratory virus.", "3,591 SRAG deaths reported YTD 2026, with 1,641 (45.7%) testing positive for a respiratory virus.", "11 of 27 Brazilian states
show SRAG at alert/risk/high-risk levels with active growth trends; 12 additional states are at elevated levels but stabilizing.", "Influenza A mortality disproportionately affects elderly (65+),
while RSV drives hospitalizations in children under 2 years.", "The influenza A share of cases has been slightly declining (22.4% \u2192 20.7%) over SE 20\u201322 as RSV becomes more dominant.",
"Rhinovirus contributes to SRAG growth especially in Alagoas, Cear\u00e1, Para\u00edba, Piau\u00ed, Sergipe, Minas Gerais, Rio de Janeiro, Santa Catarina, and Rio Grande do Sul."], "data_points":
[{"metric": "SRAG cases notified YTD 2026 (as of SE 22)", "value": 82544.0, "unit": "cases", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-
hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "SRAG cases testing positive for respiratory virus YTD (SE 22)", "value": 40259.0, "unit": "cases", "as_of": "2026-06-06", "source_url":
"https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "SRAG positivity rate YTD (SE 22)", "value": 48.8, "unit": "percent", "as_of":
"2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "SRAG deaths YTD 2026 (as of SE 22)", "value": 3591.0, "unit":
"deaths", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "SRAG deaths testing positive YTD (SE 22)",
"value": 1641.0, "unit": "deaths", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "RSV prevalence
among positive SRAG cases (last 4 EW, SE 22)", "value": 49.6, "unit": "percent", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-
influenza-e-b"}, {"metric": "Rhinovirus prevalence among positive SRAG cases (last 4 EW, SE 22)", "value": 24.5, "unit": "percent", "as_of": "2026-06-06", "source_url":
"https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "Influenza A prevalence among positive SRAG cases (last 4 EW, SE 22)", "value": 20.7,
"unit": "percent", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "Influenza B prevalence among
positive SRAG cases (last 4 EW, SE 22)", "value": 5.7, "unit": "percent", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-
influenza-e-b"}, {"metric": "SARS-CoV-2 prevalence among positive SRAG cases (last 4 EW, SE 22)", "value": 2.0, "unit": "percent", "as_of": "2026-06-06", "source_url":
"https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "Influenza A prevalence among positive SRAG deaths (last 4 EW, SE 22)", "value": 46.5,
"unit": "percent", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "Rhinovirus prevalence among
positive SRAG deaths (last 4 EW, SE 22)", "value": 18.4, "unit": "percent", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-
influenza-e-b"}, {"metric": "RSV prevalence among positive SRAG deaths (last 4 EW, SE 22)", "value": 17.0, "unit": "percent", "as_of": "2026-06-06", "source_url":
"https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "Influenza A prevalence among positive SRAG cases YTD (SE 22)", "value": 24.4, "unit":
"percent", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "Rhinovirus prevalence among positive SRAG
cases YTD (SE 22)", "value": 32.5, "unit": "percent", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric":
"RSV prevalence among positive SRAG cases YTD (SE 22)", "value": 33.1, "unit": "percent", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-
por-vsr-e-influenza-e-b"}, {"metric": "SARS-CoV-2 prevalence among positive SRAG cases YTD (SE 22)", "value": 5.7, "unit": "percent", "as_of": "2026-06-06", "source_url":
"https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "Influenza A prevalence among positive SRAG deaths YTD (SE 22)", "value": 41.9, "unit":
"percent", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "SARS-CoV-2 prevalence among positive SRAG
deaths YTD (SE 22)", "value": 21.0, "unit": "percent", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric":
"States at alert/risk/high-risk with growth trend (SE 22)", "value": 11.0, "unit": "states", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-
hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "States at alert/risk/high-risk with stabilizing/declining trend (SE 22)", "value": 12.0, "unit": "states", "as_of": "2026-06-06", "source_url":
"https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "Capitals at alert/risk/high-risk with growth signal (SE 22)", "value": 10.0, "unit":
"capitals", "as_of": "2026-06-06", "source_url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b"}, {"metric": "SRAG cases notified YTD 2026 (as of SE
21)", "value": 77153.0, "unit": "cases", "as_of": "2026-05-30", "source_url": "https://agencia.fiocruz.br/infogripe-numero-de-casos-de-srag-mantem-crescimento-no-pais"}, {"metric": "SRAG cases
notified YTD 2026 (as of SE 20)", "value": 70211.0, "unit": "cases", "as_of": "2026-05-23", "source_url": "https://agencia.fiocruz.br/infogripe-numero-de-casos-de-srag-continua-aumentando-em-todas-
faixas-etarias"}, {"metric": "RSV prevalence among positive SRAG cases (last 4 EW, SE 21)", "value": 48.5, "unit": "percent", "as_of": "2026-05-30", "source_url":
"https://agencia.fiocruz.br/infogripe-numero-de-casos-de-srag-mantem-crescimento-no-pais"}, {"metric": "RSV prevalence among positive SRAG cases (last 4 EW, SE 20)", "value": 47.6, "unit": "percent",
"as_of": "2026-05-23", "source_url": "https://agencia.fiocruz.br/infogripe-numero-de-casos-de-srag-continua-aumentando-em-todas-faixas-etarias"}, {"metric": "Rhinovirus prevalence among positive SRAG
cases (last 4 EW, SE 20)", "value": 23.9, "unit": "percent", "as_of": "2026-05-23", "source_url": "https://agencia.fiocruz.br/infogripe-numero-de-casos-de-srag-continua-aumentando-em-todas-faixas-
etarias"}, {"metric": "Influenza A prevalence among positive SRAG cases (last 4 EW, SE 20)", "value": 22.4, "unit": "percent", "as_of": "2026-05-23", "source_url":
"https://agencia.fiocruz.br/infogripe-numero-de-casos-de-srag-continua-aumentando-em-todas-faixas-etarias"}, {"metric": "States with growth trend (SE 20)", "value": 20.0, "unit": "states", "as_of":
"2026-05-23", "source_url": "https://agencia.fiocruz.br/infogripe-numero-de-casos-de-srag-continua-aumentando-em-todas-faixas-etarias"}, {"metric": "States with growth trend (SE 21)", "value": 18.0,
"unit": "states", "as_of": "2026-05-30", "source_url": "https://agencia.fiocruz.br/infogripe-numero-de-casos-de-srag-mantem-crescimento-no-pais"}], "created_at": "2026-06-15T02:47:08.040482Z",
"updated_at": "2026-06-15T02:47:08.040482Z", "stale_after": "2026-06-15T08:47:08.040482Z", "state": "fresh", "revision_history": [], "session_id": "7844b104-fa00-443e-9333-8d4d9cc3f00c",
"follow_up_count": 0}, "is_follow_up": false}, {"query": "Brazil respiratory virus seasonality influenza A rhinovirus transition winter June July historical pattern InfoGripe", "entry": {"slug":
"brazil-respiratory-virus-seasonality-influenza-a-r-79d6700a", "query": "Brazil respiratory virus seasonality influenza A rhinovirus transition winter June July historical pattern InfoGripe",
"answer": "Now I have comprehensive information from the research agents. Let me compile the final synthesis.\n\n---\n\n# Brazil Respiratory Virus Seasonality: Influenza A\u2013Rhinovirus Transition
in Winter (June\u2013July) \u2014 InfoGripe Historical Patterns\n\n## 1. The InfoGripe Surveillance System\n\n**InfoGripe** is operated by Fiocruz (Funda\u00e7\u00e3o Oswaldo Cruz) through its
Programa de Computa\u00e7\u00e3o Cient\u00edfica (PROCC) in collaboration with EMAp/FGV. It tracks **SARI (Severe Acute Respiratory Infection)** hospitalizations nationally using data from the SIVEP-
Gripe notification system. Cases are virologically typed into influenza A (H1N1pdm09, H3N2), influenza B, RSV, rhinovirus/enterovirus, SARS-CoV-2, and other respiratory viruses. Data is available at
national, state, and capital-city levels by epidemiological week (EW).\n\n**Key methodology**: InfoGripe employs Bayesian nowcasting models to correct for reporting delays (Bastos et al., *Statistics
in Medicine*, 2019; doi: 10.1002/sim.8303), making it one of the most robust real-time respiratory surveillance systems in Latin America.\n\n---\n\n## 2. Canonical Seasonal Sequence in Brazil's
South/Southeast\n\nBrazil's respiratory virus epidemiology follows a consistent **sequential dominance pattern** in the South and Southeast regions:\n\n| Period | Epidemiological Weeks | Dominant
Virus |\n|--------|----------------------|----------------|\n| Late summer/early autumn | EW 8\u201318 (Feb\u2013Apr) | **RSV** peaks |\n| Autumn | EW 10\u201320 (Mar\u2013May) | **Rhinovirus**
prominent; overlaps with RSV decline |\n| **Transition window** | **EW 18\u201324 (late Apr\u2013mid Jun)** | **Rhinovirus declining \u2192 Influenza A rising** |\n| **Core winter** | **EW 24\u201330
(mid Jun\u2013late Jul)** | **Influenza A dominates** |\n| Late winter/spring | EW 30\u201336 (Aug\u2013Sep) | Influenza A waning |\n| Spring | EW 36\u201344 (Sep\u2013Nov) | **Rhinovirus resurgence**
(second wave) |\n| Summer | EW 44\u20138 (Nov\u2013Feb) | Low-level multi-virus circulation |\n\n**Regional nuance**: In the North/Northeast (equatorial/tropical), influenza and RSV peaks occur
earlier (rainy season, ~March\u2013May), and seasonality is less defined. The transition pattern is clearest in southern Brazil (latitude effect; Almeida et al., *BMC Infectious Diseases*,
2018).\n\n---\n\n## 3. Historical Influenza A Peak Timing (National SARI Data)\n\n| Year | Dominant Subtype | Peak EW (approx.) | Calendar Period | Notes
|\n|------|------------------|--------------------|-----------------|-------|\n| 2016 | H1N1pdm09 | EW 22\u201325 | June | Strong season |\n| 2019 | H1N1pdm09 | EW 21\u201326 | May\u2013June | Last
pre-pandemic season |\n| 2020 | H1N1pdm09/COVID | EW 14\u201318 | April (truncated) | Influenza suppressed by COVID lockdowns |\n| 2021 | H3N2 (late surge) | EW 49\u201352 | December | Anomalous off-
season outbreak |\n| 2022 | H3N2 \u2192 H1N1 | EW 1\u20134, then EW 22\u201328 | Jan + Jun\u2013Jul | Two peaks; H3N2 carryover then H1N1 winter |\n| 2023 | H1N1pdm09 | EW 10\u201320 | Mar\u2013May |
Earlier than typical |\n| 2024 | H3N2 | EW 24\u201330 | Jun\u2013Jul | Classic winter timing; \"return to pre-pandemic seasonality\" |\n\nPre-pandemic baseline SARI hospitalizations peaked at
approximately **3,000\u20135,000 per week nationally** during peak influenza weeks. Annual SARI totals in pre-pandemic years were approximately **85,000\u201395,000** hospitalizations.\n\n---\n\n## 4.
The Rhinovirus\u2013Influenza \"Replacement\" Pattern (Viral Interference)\n\nThis is one of the most epidemiologically significant phenomena visible in InfoGripe data:\n\n### Mechanism\n-
**Interferon-mediated viral interference**: Rhinovirus infection triggers innate immune responses (particularly type I and type III interferon signaling) in the respiratory epithelium, transiently
suppressing influenza replication at the population level. The converse also occurs \u2014 influenza epidemics suppress rhinovirus co-circulation.\n- Landmark evidence: **Nickbakhsh et al. (2019,
PNAS)** demonstrated that influenza A infection reduced odds of rhinovirus co-detection by ~70% using 9 years of Scottish data.\n- **Dai/Piret & Boivin (2022, Emerging Infectious Diseases)** showed
rhinovirus epidemics can delay influenza onset by 1\u20132 weeks.\n\n### Brazil-Specific Evidence from InfoGripe\n- **2022 season**: Rhinovirus dominated SARI in the South/Southeast during EW
8\u201316 (late Feb\u2013mid Apr), then declined as influenza A (H3N2, then H1N1) rose by EW 20\u201328.\n- **2023 season**: Strong early rhinovirus wave (EW 8\u201315) followed by early influenza A
(H1N1) from EW 15\u201322.\n- **2024 season**: Rhinovirus prominent in SARI detections through EW 14\u201320; influenza A (H3N2) took over from EW 22 onward.\n- **2020\u20132021 natural experiment**:
When COVID lockdowns suppressed influenza, rhinovirus rapidly filled the ecological niche and became the dominant SARI pathogen in children.\n\n### The Critical Transition Window\nThe transition from
rhinovirus dominance to influenza A dominance typically occurs during **EW 18\u201324 (late April to mid-June)**:\n- Rhinovirus detections decline as a proportion of SARI cases\n- Influenza A
detections rise\n- A brief overlap period (~2\u20133 weeks) occurs\n- By **EW 24\u201326 (mid to late June)**, influenza A is clearly the dominant respiratory pathogen\n\n---\n\n## 5. Age-Stratified
Patterns\n\n| Age Group | Dominant Winter Pathogen | Notes |\n|-----------|------------------------|-------|\n| < 2 years | RSV, rhinovirus | RSV #1 cause of SARI; rhinovirus significant year-round
|\n| 2\u201314 years | Influenza A, rhinovirus | Both contribute substantially to SARI |\n| 15\u201359 years | Influenza A | Dominates SARI during winter |\n| \u2265 60 years | Influenza A (+COVID-19
post-pandemic) | Highest mortality impact |\n\n---\n\n## 6. Current Context (June 15, 2026)\n\nBased on historical patterns, as of mid-June 2026 (approximately EW 24):\n- Brazil should be **at or near
peak influenza A activity** in the South/Southeast\n- **Rhinovirus should have declined** from its autumn peak (March\u2013May)\n- **RSV season should be largely concluded** in most regions\n- The
dominant influenza A subtype for 2026 would need confirmation from current InfoGripe bulletins\n\n**\u26a0 Caveat**: Live 2025\u20132026 data was not retrievable due to tool limitations. For current
data, consult:\n- InfoGripe Dashboard: `https://info.gripe.fiocruz.br/`\n- WHO FluNet: `https://www.who.int/tools/flunet`\n- OpenDataSUS SIVEP-Gripe:
`https://opendatasus.saude.gov.br/dataset/srag`\n\n---", "sources": [{"url": "https://info.gripe.fiocruz.br/", "title": "InfoGripe Dashboard - Fiocruz PROCC/EMAp-FGV", "domain":
"info.gripe.fiocruz.br", "accessed_at": "2026-06-15T00:00:00Z", "snippet": "Weekly SARI surveillance with nowcasting for Brazil, broken down by viral etiology, age group, state, and epidemiological
week. Primary source for respiratory virus seasonality data."}, {"url": "https://doi.org/10.1073/pnas.1911083116", "title": "Nickbakhsh et al. (2019) - Virus-virus interactions impact the population
dynamics of influenza and the common cold", "domain": "pnas.org", "accessed_at": "2026-06-15T00:00:00Z", "snippet": "Demonstrated negative ecological interaction between influenza A and rhinovirus;
influenza A infection reduced odds of rhinovirus co-detection by ~70%."}, {"url": "https://doi.org/10.1002/sim.8303", "title": "Bastos et al. (2019) - A modelling approach for correcting reporting
delays in disease surveillance data", "domain": "onlinelibrary.wiley.com", "accessed_at": "2026-06-15T00:00:00Z", "snippet": "Core methodology paper for InfoGripe's Bayesian nowcasting approach to
correct SARI reporting delays."}, {"url": "https://doi.org/10.1186/s12879-018-3484-z", "title": "Almeida et al. (2018) - Seasonal dynamics of influenza in Brazil: the latitude effect", "domain":
"bmcinfectdis.biomedcentral.com", "accessed_at": "2026-06-15T00:00:00Z", "snippet": "Demonstrated latitude-dependent seasonality of influenza in Brazil, with year-round circulation in equatorial
regions and defined winter peaks in southern regions."}, {"url": "https://doi.org/10.3201/eid2802.211727", "title": "Piret & Boivin (2022) - Viral Interference between Respiratory Viruses", "domain":
"wwwnc.cdc.gov", "accessed_at": "2026-06-15T00:00:00Z", "snippet": "Review of viral interference mechanisms; rhinovirus epidemics can delay influenza epidemic onset by 1-2 weeks through interferon-
mediated population-level priming."}, {"url": "https://www.who.int/tools/flunet", "title": "WHO FluNet - Global Influenza Virological Surveillance", "domain": "who.int", "accessed_at":
"2026-06-15T00:00:00Z", "snippet": "Lab-confirmed influenza surveillance data by type/subtype for Brazil and globally."}, {"url": "https://opendatasus.saude.gov.br/dataset/srag", "title": "OpenDataSUS
SIVEP-Gripe - SARI Raw Data", "domain": "opendatasus.saude.gov.br", "accessed_at": "2026-06-15T00:00:00Z", "snippet": "Open case-level SARI hospitalization data from Brazil's Ministry of Health
notification system."}, {"url": "https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/g/gripe-influenza", "title": "Brazil Ministry of Health - Influenza Epidemiological Situation", "domain":
"gov.br", "accessed_at": "2026-06-15T00:00:00Z", "snippet": "Official epidemiological bulletins on influenza situation in Brazil from the Ministry of Health."}], "key_facts": ["Brazil's influenza A
season peaks during epidemiological weeks 24-28 (mid-June to mid-July) in the South/Southeast, following the Southern Hemisphere winter pattern.", "The rhinovirus-to-influenza A transition window
typically occurs during EW 18-24 (late April to mid-June), with influenza A clearly dominant by mid-to-late June.", "Viral interference (interferon-mediated) creates a 'see-saw' or replacement
pattern: rhinovirus and influenza A rarely co-circulate at high levels simultaneously.", "Brazil's canonical respiratory virus sequence is: RSV (Feb-Apr) \u2192 Rhinovirus (Mar-May) \u2192 Influenza A
(May-Aug) \u2192 Rhinovirus resurgence (Sep-Nov).", "InfoGripe/Fiocruz (SIVEP-Gripe) is Brazil's primary SARI surveillance system, providing weekly nowcasted data by virus, age group, and geography.",
"In 2024, the influenza A season (H3N2 dominant) peaked around EW 24-30 (June-July), described as a 'return to pre-pandemic seasonality'.", "Pre-pandemic annual SARI hospitalizations were
approximately 85,000-95,000 nationally, with peak weeks seeing 3,000-5,000 hospitalizations.", "Rhinovirus is the leading cause of SARI in children aged 0-4 during non-influenza periods; influenza A
dominates adult SARI during winter.", "Regional variation is significant: North/Northeast regions show earlier, rain-driven peaks (Mar-May), while South/Southeast follows classic winter timing (Jun-
Aug).", "Nickbakhsh et al. (2019, PNAS) demonstrated influenza A infection reduced odds of rhinovirus co-detection by approximately 70%.", "During COVID lockdowns (2020-2021), rhinovirus filled the
ecological niche vacated by suppressed influenza, becoming the dominant SARI pathogen in children.", "Post-pandemic years (2022-2024) showed gradual return to pre-pandemic seasonal respiratory virus
patterns in Brazil."], "data_points": [{"metric": "Typical influenza A peak epidemiological week range (South/Southeast Brazil)", "value": 26.0, "unit": "epidemiological week (midpoint of EW 24-28)",
"as_of": "2019-12-31", "source_url": "https://info.gripe.fiocruz.br/"}, {"metric": "Pre-pandemic annual SARI hospitalizations (national)", "value": 90000.0, "unit": "hospitalizations per year (approx.
midpoint of 85k-95k range)", "as_of": "2019-12-31", "source_url": "https://info.gripe.fiocruz.br/"}, {"metric": "Peak week SARI hospitalizations (pre-pandemic)", "value": 4000.0, "unit":
"hospitalizations per week (midpoint of 3k-5k range)", "as_of": "2019-12-31", "source_url": "https://info.gripe.fiocruz.br/"}, {"metric": "Reduction in rhinovirus co-detection odds during influenza A
infection", "value": 70.0, "unit": "percent reduction", "as_of": "2019-12-16", "source_url": "https://doi.org/10.1073/pnas.1911083116"}, {"metric": "Rhinovirus-to-influenza transition window start
(typical)", "value": 18.0, "unit": "epidemiological week", "as_of": "2024-07-31", "source_url": "https://info.gripe.fiocruz.br/"}, {"metric": "Rhinovirus-to-influenza transition window end (typical)",
"value": 24.0, "unit": "epidemiological week", "as_of": "2024-07-31", "source_url": "https://info.gripe.fiocruz.br/"}, {"metric": "2024 influenza A peak week (H3N2 dominant, national)", "value": 27.0,
"unit": "epidemiological week (midpoint of EW 24-30)", "as_of": "2024-07-31", "source_url": "https://info.gripe.fiocruz.br/"}, {"metric": "2023 influenza A peak week (H1N1, earlier than typical)",
"value": 15.0, "unit": "epidemiological week (midpoint of EW 10-20)", "as_of": "2023-05-31", "source_url": "https://info.gripe.fiocruz.br/"}, {"metric": "2022 SARI hospitalizations (national, mixed
COVID+influenza+RSV)", "value": 180000.0, "unit": "hospitalizations per year (approx.)", "as_of": "2022-12-31", "source_url": "https://info.gripe.fiocruz.br/"}, {"metric": "Influenza delay from
rhinovirus interference", "value": 1.5, "unit": "weeks (midpoint of 1-2 week range)", "as_of": "2022-07-01", "source_url": "https://doi.org/10.3201/eid2802.211727"}], "created_at":
"2026-06-15T02:44:48.332642Z", "updated_at": "2026-06-15T02:44:48.332642Z", "stale_after": "2026-06-18T02:44:48.332642Z", "state": "fresh", "revision_history": [], "session_id":
"7cb6457e-8091-4ef7-8c57-0ccda98beb6c", "follow_up_count": 0}, "is_follow_up": false}], "successful_count": 2, "failed_count": 0}
```

## 🔧 Tool: mcp__notes__reflection


```json
{
  "factors": [
    {
      "description": "RSV (VSR) is currently dominant at 49.6% of positive SRAG cases in the most recent 4-week window (SE 22, published June 11), with a strong rising trend (47.6% \u2192 48.5% \u2192 49.6% over SE 20-22). This is massive lead over all other viruses.",
      "supports": "VSR (RSV)",
      "logit": 2.5,
      "confidence": 0.95
    },
    {
      "description": "Rhinovirus is at 24.5% in recent 4-week window (SE 22) - second place but nearly half of RSV's share. Historically rhinovirus declines as winter deepens and influenza rises.",
      "supports": "Rhinovirus (Rinov\u00edrus)",
      "logit": 0.5,
      "confidence": 0.7
    },
    {
      "description": "Influenza A at 20.7% in recent 4-week window, and its share has been DECLINING (22.4% \u2192 21.9% \u2192 20.7% over SE 20-22) as RSV becomes more dominant. However, historically influenza A peaks EW 24-28, so it may still rise.",
      "supports": "Influenza A",
      "logit": 0.3,
      "confidence": 0.6
    },
    {
      "description": "The question description says rhinovirus was at 33.2% and influenza A at 20.5% in the SE 22 bulletin, but the actual research found the 4-week window shows RSV at 49.6%, rhinovirus at 24.5%, influenza A at 20.7%. The question description numbers appear to be YTD/cumulative figures, not the 4-week window. Resolution is based on the 4-week window.",
      "supports": "VSR (RSV)",
      "logit": 1.5,
      "confidence": 0.85
    },
    {
      "description": "Seasonally, RSV typically peaks in autumn/early winter in Brazil (EW 14-20 in S/SE). However, the current data shows RSV still RISING at EW 22. In the target bulletin (EW 23-25), RSV could be at or past peak but still dominant.",
      "supports": "VSR (RSV)",
      "logit": 1,
      "confidence": 0.75
    },
    {
      "description": "The target bulletin will be published on or before June 25 (likely June 18 for SE 23, or June 25 for SE 24). The 4-week rolling window will include approximately EW 20-23 or EW 21-24. RSV's lead is so large (~50% vs ~25% rhinovirus) that even with some decline, it would likely remain dominant.",
      "supports": "VSR (RSV)",
      "logit": 1.5,
      "confidence": 0.85
    },
    {
      "description": "Influenza B rising (5.7%) and other viruses very low. Virtually no chance any non-named virus leads.",
      "supports": "Any other virus (Influenza B, SARS-CoV-2, or other)",
      "logit": -3,
      "confidence": 0.95
    }
  ],
  "tentative_estimate": {
    "probabilities": {
      "Rhinovirus (Rinov\u00edrus)": 0.05,
      "Influenza A": 0.05,
      "VSR (RSV)": 0.88,
      "Any other virus (Influenza B, SARS-CoV-2, or other)": 0.02
    }
  },
  "assessment": "The critical insight here is distinguishing between the question description's numbers (which appear to cite YTD/cumulative figures showing rhinovirus at 33.2%) and the actual resolution criteria which uses the \"most recent 4-week window\" (\u00faltimas 4 semanas). The research confirms that in the most recent 4-week window as of SE 22, RSV dominates at 49.6%, nearly double rhinovirus at 24.5%.\n\nRSV has been trending upward in the 4-week window (47.6% \u2192 48.5% \u2192 49.6% over SE 20-22), and its lead is so substantial that even a moderate decline in the next 1-2 weeks would not change its dominant position. The target bulletin (published on or before June 25) will cover approximately SE 23 or SE 24. Given the rolling 4-week window, RSV's dominance is locked in for the short term.\n\nThe main risk would be if the question description's numbers (rhinovirus 33.2%) are actually the correct 4-week window figures, but the research clearly contradicts this, showing those as YTD cumulative figures. The resolution criteria explicitly specify the 4-week window, so RSV should be the answer.\n\nInfluenza A is seasonally rising but currently declining as a share, and it would need to more than double to overtake RSV - extremely unlikely in 1-2 weeks. Rhinovirus has been stable at ~24% and declining seasonally.",
  "anchor": "RSV currently at 49.6% in 4-week window with strong trend - very likely to remain dominant in the next 1-2 bulletins",
  "calibration_notes": "The main calibration concern is whether the question description's figures (rhinovirus 33.2%) vs the research findings (rhinovirus 24.5% in 4-week, RSV 49.6%) represent a discrepancy in what the resolution source actually reports. Need to verify which set of numbers appears in the actual bulletin as the '4-week window' figures. If the question author's stated numbers ARE the 4-week window figures, then the answer shifts dramatically toward rhinovirus.",
  "key_uncertainties": "1. Which numbers (YTD cumulative vs 4-week rolling) does the bulletin actually report as the '\u00faltimas 4 semanas' virus distribution? The question says rhinovirus 33.2%, research found RSV 49.6% in the 4-week window.\n2. How quickly could RSV decline or influenza A rise in 1-2 weeks?",
  "tool_audit": "research() returned excellent data from three consecutive InfoGripe bulletins (SE 20-22), including detailed virus prevalence breakdowns for both 4-week window and YTD. The seasonality research was comprehensive. However, there is a discrepancy between the question description's stated figures and the research findings that needs investigation.",
  "process_reflection": "The research tool was very effective here, directly accessing the Fiocruz bulletin pages and extracting detailed data. The key tension is the discrepancy between the question description and research findings. I need to resolve this before submitting."
}
```

### 📋 Result

```
{"factor_count": 7, "factor_sum": 3.355, "neutral_factor_count": 0, "factor_breakdown": [{"description": "RSV (VSR) is currently dominant at 49.6% of positive SRAG cases in the most recent 4-week
window (SE 22, published June 11), with a strong rising trend (47.6% \u2192 48.5% \u2192 49.6% over SE 20-22). This is massive lead over all other viruses.", "supports": "VSR (RSV)", "logit": 2.5,
"confidence": 0.95, "effective_logit": 2.375}, {"description": "Rhinovirus is at 24.5% in recent 4-week window (SE 22) - second place but nearly half of RSV's share. Historically rhinovirus declines
as winter deepens and influenza rises.", "supports": "Rhinovirus (Rinov\u00edrus)", "logit": 0.5, "confidence": 0.7, "effective_logit": 0.35}, {"description": "Influenza A at 20.7% in recent 4-week
window, and its share has been DECLINING (22.4% \u2192 21.9% \u2192 20.7% over SE 20-22) as RSV becomes more dominant. However, historically influenza A peaks EW 24-28, so it may still rise.",
"supports": "Influenza A", "logit": 0.3, "confidence": 0.6, "effective_logit": 0.18}, {"description": "The question description says rhinovirus was at 33.2% and influenza A at 20.5% in the SE 22
bulletin, but the actual research found the 4-week window shows RSV at 49.6%, rhinovirus at 24.5%, influenza A at 20.7%. The question description numbers appear to be YTD/cumulative figures, not the
4-week window. Resolution is based on the 4-week window.", "supports": "VSR (RSV)", "logit": 1.5, "confidence": 0.85, "effective_logit": 1.275}, {"description": "Seasonally, RSV typically peaks in
autumn/early winter in Brazil (EW 14-20 in S/SE). However, the current data shows RSV still RISING at EW 22. In the target bulletin (EW 23-25), RSV could be at or past peak but still dominant.",
"supports": "VSR (RSV)", "logit": 1.0, "confidence": 0.75, "effective_logit": 0.75}, {"description": "The target bulletin will be published on or before June 25 (likely June 18 for SE 23, or June 25
for SE 24). The 4-week rolling window will include approximately EW 20-23 or EW 21-24. RSV's lead is so large (~50% vs ~25% rhinovirus) that even with some decline, it would likely remain dominant.",
"supports": "VSR (RSV)", "logit": 1.5, "confidence": 0.85, "effective_logit": 1.275}, {"description": "Influenza B rising (5.7%) and other viruses very low. Virtually no chance any non-named virus
leads.", "supports": "Any other virus (Influenza B, SARS-CoV-2, or other)", "logit": -3.0, "confidence": 0.95, "effective_logit": -2.8499999999999996}], "dominant_factor": "Influenza B rising (5.7%)
and other viruses very low. Virtually no chance any non-named virus leads.", "dominant_effective_logit": -2.8499999999999996, "outcome_breakdown": [{"outcome": "VSR (RSV)", "factor_count": 4,
"logit_sum": 5.675, "factors": [{"description": "RSV (VSR) is currently dominant at 49.6% of positive SRAG cases in the most recent 4-week window (SE 22, published June 11), with a strong rising trend
(47.6% \u2192 48.5% \u2192 49.6% over SE 20-22). This is massive lead over all other viruses.", "supports": "VSR (RSV)", "logit": 2.5, "confidence": 0.95, "effective_logit": 2.375}, {"description":
"The question description says rhinovirus was at 33.2% and influenza A at 20.5% in the SE 22 bulletin, but the actual research found the 4-week window shows RSV at 49.6%, rhinovirus at 24.5%,
influenza A at 20.7%. The question description numbers appear to be YTD/cumulative figures, not the 4-week window. Resolution is based on the 4-week window.", "supports": "VSR (RSV)", "logit": 1.5,
"confidence": 0.85, "effective_logit": 1.275}, {"description": "Seasonally, RSV typically peaks in autumn/early winter in Brazil (EW 14-20 in S/SE). However, the current data shows RSV still RISING at
EW 22. In the target bulletin (EW 23-25), RSV could be at or past peak but still dominant.", "supports": "VSR (RSV)", "logit": 1.0, "confidence": 0.75, "effective_logit": 0.75}, {"description": "The
target bulletin will be published on or before June 25 (likely June 18 for SE 23, or June 25 for SE 24). The 4-week rolling window will include approximately EW 20-23 or EW 21-24. RSV's lead is so
large (~50% vs ~25% rhinovirus) that even with some decline, it would likely remain dominant.", "supports": "VSR (RSV)", "logit": 1.5, "confidence": 0.85, "effective_logit": 1.275}]}, {"outcome":
"Rhinovirus (Rinov\u00edrus)", "factor_count": 1, "logit_sum": 0.35, "factors": [{"description": "Rhinovirus is at 24.5% in recent 4-week window (SE 22) - second place but nearly half of RSV's share.
Historically rhinovirus declines as winter deepens and influenza rises.", "supports": "Rhinovirus (Rinov\u00edrus)", "logit": 0.5, "confidence": 0.7, "effective_logit": 0.35}]}, {"outcome": "Influenza
A", "factor_count": 1, "logit_sum": 0.18, "factors": [{"description": "Influenza A at 20.7% in recent 4-week window, and its share has been DECLINING (22.4% \u2192 21.9% \u2192 20.7% over SE 20-22) as
RSV becomes more dominant. However, historically influenza A peaks EW 24-28, so it may still rise.", "supports": "Influenza A", "logit": 0.3, "confidence": 0.6, "effective_logit": 0.18}]}, {"outcome":
"Any other virus (Influenza B, SARS-CoV-2, or other)", "factor_count": 1, "logit_sum": -2.8499999999999996, "factors": [{"description": "Influenza B rising (5.7%) and other viruses very low. Virtually
no chance any non-named virus leads.", "supports": "Any other virus (Influenza B, SARS-CoV-2, or other)", "logit": -3.0, "confidence": 0.95, "effective_logit": -2.8499999999999996}]}],
"mc_distribution_metrics": {"implied_probabilities": {"Influenza A": 0.004069918817874818, "Any other virus (Influenza B, SARS-CoV-2, or other)": 0.00019664072480691353, "VSR (RSV)":
0.9909093459380112, "Rhinovirus (Rinov\u00edrus)": 0.004824094519307068}, "tentative_probabilities": {"Rhinovirus (Rinov\u00edrus)": 0.05, "Influenza A": 0.05, "VSR (RSV)": 0.88, "Any other virus
(Influenza B, SARS-CoV-2, or other)": 0.02}, "per_option_gap_pp": {"Influenza A": 4.593008118212519, "Any other virus (Influenza B, SARS-CoV-2, or other)": 1.9803359275193086, "VSR (RSV)":
-11.090934593801116, "Rhinovirus (Rinov\u00edrus)": 4.517590548069293}, "max_gap_pp": -11.090934593801116, "max_gap_option": "VSR (RSV)"}, "sources": ["[(Metaculus) In the InfoGripe bulletin published
on or immediately before June 25, 2026, which respiratory virus will be the single most prevalent among positive SRAG cases nationally over the most recent 4-week
window?](https://www.metaculus.com/questions/44052)"]}
```

## 💬 Response

Wait — I need to carefully reconcile the discrepancy between the question description and the research findings. The question description says rhinovirus was at 33.2%, but research found RSV at 49.6% in the 4-week window. Let me verify which numbers are the actual 4-week window figures by checking the bulletin directly.

## 🔧 Tool: mcp__search__fetch_url


## 🔧 Tool: mcp__search__fetch_url


```json
{
  "url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b",
  "prompt": "What are the exact percentages for each respiratory virus (rhinovirus, influenza A, influenza B, RSV/VSR, SARS-CoV-2) among positive SRAG cases in the most recent 4-week window (\u00faltimas 4 semanas epidemiol\u00f3gicas)? Also distinguish between the 4-week window figures and the year-to-date (YTD) cumulative figures. What epidemiological week does this bulletin cover?"
}
```

### 📋 Result

```
{"url": "https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b", "content": "Based on the content, here are the respiratory virus
percentages:\n\n**Epidemiological Week Coverage:** Week 22 (May 31 - June 6, 2026)\n\n**Most Recent 4-Week Window (\u00faltimas quatro semanas epidemiol\u00f3gicas):**\nAmong positive SRAG cases:\n-
Influenza A: 20.7%\n- Influenza B: 5.7%\n- RSV/VSR: 49.6%\n- Rhinovirus: 24.5%\n- SARS-CoV-2 (COVID-19): 2.0%\n\n**Year-to-Date 2026 (cumulative):**\nAmong positive SRAG cases:\n- Influenza A:
24.4%\n- Influenza B: 3.1%\n- RSV/VSR: 33.1%\n- Rhinovirus: 32.5%\n- SARS-CoV-2 (COVID-19): 5.7%\n\n**Key difference:** In the most recent 4 weeks, RSV/VSR has become significantly more dominant
(49.6% vs 33.1% YTD), while rhinovirus has decreased (24.5% vs 32.5% YTD) and COVID-19 has dropped substantially (2.0% vs 5.7% YTD).\n\n**Relevant links:**\n- [Boletim InfoGripe 2026 Week 22
(PDF)](https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_22.pdf)", "title": "InfoGripe: cresce n\u00famero de hospitaliza\u00e7\u00f5es por VSR e influenza A e B"}
```

```json
{
  "url": "https://agencia.fiocruz.br/infogripe",
  "prompt": "What is the most recent InfoGripe bulletin published? What epidemiological week does it cover? Any newer bulletins after SE 22?"
}
```

### 📋 Result

```
{"url": "https://agencia.fiocruz.br/infogripe", "content": "Based on the content provided:\n\n**Most recent InfoGripe bulletin:** Published on Thursday, November 14th (14/11)\n\n**Epidemiological week
covered:** SE 45 (Semana Epidemiol\u00f3gica 45), which corresponds to the period from November 3-9 (3 a 9 de novembro)\n\n**Newer bulletins after SE 22:** Yes, SE 45 is significantly more recent than
SE 22. SE 45 occurred in November, which is approximately 23 weeks after SE 22 (SE 22 would have been around late May/early June).\n\n**Relevant links:**\n- [InfoGripe Bulletin 2024 Week 45
(PDF)](https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/u91/resumo_infogripe_2024_45.pdf)", "title": "InfoGripe: Rio de Janeiro mant\u00e9m curva de crescimento de Covid-19 entre idosos"}
```

## 🔧 Tool: mcp__search__web_search


```json
{
  "query": "InfoGripe Fiocruz boletim semana epidemiol\u00f3gica 23 2026 junho"
}
```

### 📋 Result

```
{"query": "InfoGripe Fiocruz boletim semana epidemiol\u00f3gica 23 2026 junho", "results": [{"title": "Resumo do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 14 2026", "url":
"https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_14_0.pdf", "snippet": null, "api_data": null, "hint": null}, {"title": "Resumo do Boletim InfoGripe -- Semana
Epidemiol\u00f3gica (SE) 19 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_19.pdf", "snippet": null, "api_data": null, "hint": null}, {"title": "Resumo
do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 20 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_20.pdf", "snippet": null, "api_data": null,
"hint": null}, {"title": "Resumo do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 11 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_11.pdf",
"snippet": null, "api_data": null, "hint": null}, {"title": "Resumo do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 18 2026", "url":
"https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_18.pdf", "snippet": null, "api_data": null, "hint": null}, {"title": "Resumo do Boletim InfoGripe -- Semana
Epidemiol\u00f3gica (SE) 04 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_04.pdf", "snippet": null, "api_data": null, "hint": null}, {"title": "Resumo
do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 16 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_16.pdf", "snippet": null, "api_data": null,
"hint": null}, {"title": "Resumo do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 02 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_02.pdf",
"snippet": null, "api_data": null, "hint": null}, {"title": "Resumo do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 07 2026", "url":
"https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_07.pdf", "snippet": null, "api_data": null, "hint": null}]}
```

## 🔧 Tool: mcp__search__fetch_url


## 🔧 Tool: mcp__search__web_search


```json
{
  "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_22.pdf",
  "prompt": "What are the exact percentages for each respiratory virus (rhinovirus, influenza A, influenza B, RSV/VSR, SARS-CoV-2) among positive SRAG cases in the most recent 4-week window? What does the bulletin report as the virus prevalence distribution?"
}
```

### 📋 Result

```
{"format": "pdf", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_22.pdf", "pdf_path": "/home/pfftz/job/onit/aib-joy-void-joy-
bot.git/tree/main/logs/44052_20260615_023818/downloads/pdf/4d758459bc8f.pdf", "hint": "PDF downloaded to /home/pfftz/job/onit/aib-joy-void-joy-
bot.git/tree/main/logs/44052_20260615_023818/downloads/pdf/4d758459bc8f.pdf. Use the Read tool to read the PDF content."}
```

```json
{
  "query": "\"InfoGripe\" \"semana 23\" OR \"semana epidemiol\u00f3gica 23\" 2026 site:agencia.fiocruz.br"
}
```

### 📋 Result

```
{"query": "\"InfoGripe\" \"semana 23\" OR \"semana epidemiol\u00f3gica 23\" 2026 site:agencia.fiocruz.br", "results": [{"title": "Resumo do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 20
2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_20.pdf", "snippet": null, "api_data": null, "hint": null}, {"title": "Resumo do Boletim InfoGripe --
Semana Epidemiol\u00f3gica (SE) 19 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_19.pdf", "snippet": null, "api_data": null, "hint": null}, {"title":
"Resumo do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 02 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_02.pdf", "snippet": null, "api_data":
null, "hint": null}, {"title": "Resumo do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 16 2026", "url":
"https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_16.pdf", "snippet": null, "api_data": null, "hint": null}, {"title": "Resumo do Boletim InfoGripe -- Semana
Epidemiol\u00f3gica (SE) 14 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_14_0.pdf", "snippet": null, "api_data": null, "hint": null}, {"title":
"Resumo do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 08 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_08_0.pdf", "snippet": null,
"api_data": null, "hint": null}, {"title": "Resumo do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 04 2026", "url":
"https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_04.pdf", "snippet": null, "api_data": null, "hint": null}, {"title": "Resumo do Boletim InfoGripe -- Semana
Epidemiol\u00f3gica (SE) 18 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_18.pdf", "snippet": null, "api_data": null, "hint": null}, {"title": "Resumo
do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 13 2026", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_13_0.pdf", "snippet": null, "api_data": null,
"hint": null}, {"title": "Resumo do Boletim InfoGripe -- Semana Epidemiol\u00f3gica (SE) 45 2025", "url": "https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2025_45.pdf",
"snippet": null, "api_data": null, "hint": null}]}
```

## 🔧 Tool: Read


```json
{
  "file_path": "/home/pfftz/job/onit/aib-joy-void-joy-bot.git/tree/main/logs/44052_20260615_023818/downloads/pdf/4d758459bc8f.pdf"
}
```

### 📋 Result

```
PDF file read: /home/pfftz/job/onit/aib-joy-void-joy-bot.git/tree/main/logs/44052_20260615_023818/downloads/pdf/4d758459bc8f.pdf (4.1MB)
```

## 💭 Thinking

Now I have the actual PDF of the SE 22 bulletin, and I can confirm the data directly from the source. Let me analyze the key discrepancy:

The question description states: "Among positive cases over the most recent 4 weeks it reported approximately: rhinovirus 33.2%, influenza A 20.5%, VSR 8.5%, influenza B 2.6%"

But the actual bulletin PDF (page 3) clearly states: "Nas 4 últimas semanas epidemiológicas, a prevalência entre os casos positivos foi de 20,7% de Influenza A, 5,7% de Influenza B, 49,6% de vírus sincicial respiratório, 24,5% de Rinovírus, e 2% de SARS-CoV-2 (COVID-19)."
The actual 4-week figures show RSV at 49.6%, rhinovirus at 24.5%, influenza A at 20.7%, and influenza B at 5.7%—completely different from what the question claims. The description's numbers appear to be either incorrect or sourced from elsewhere, possibly mixing in year-to-date data.

Since the resolution criteria specifically requires the highest prevalence from the most recent four-week window in a bulletin published by June 25, and the current SE 22 bulletin clearly shows RSV leading at 49.6%, that's what matters for the resolution. The next bulletin (SE 23 or SE 24) will likely confirm this trend given how dominant RSV currently is.

## 💬 Response

Excellent - I now have the actual SE 22 bulletin PDF confirming the data. The question description's numbers are **incorrect** - it states "rhinovirus 33.2%, influenza A 20.5%, VSR 8.5%" but the actual bulletin clearly reports for the 4-week window: **RSV 49.6%**, rhinovirus 24.5%, influenza A 20.7%. RSV is overwhelmingly dominant.

Let me update my reflection with this confirmed data.

## 🔧 Tool: mcp__notes__reflection


```json
{
  "factors": [
    {
      "description": "RSV (VSR) is confirmed at 49.6% of positive SRAG cases in the 4-week window (SE 22 bulletin PDF, page 3), nearly double the second-place rhinovirus at 24.5%. This is a massive, confirmed lead from the primary resolution source.",
      "supports": "VSR (RSV)",
      "logit": 3,
      "confidence": 0.95
    },
    {
      "description": "RSV trend is upward: 47.6% (SE 20) \u2192 48.5% (SE 21) \u2192 49.6% (SE 22). RSV is still actively rising, driven by ongoing increases in Nordeste, Sudeste, and Sul regions.",
      "supports": "VSR (RSV)",
      "logit": 1.5,
      "confidence": 0.85
    },
    {
      "description": "The rolling 4-week window creates enormous inertia. Even if RSV peaked at SE 22, the 4-week average would only decline gradually. To lose its lead, RSV would need to drop from ~50% to below ~25% in 1-2 weeks - mathematically impossible with a rolling average.",
      "supports": "VSR (RSV)",
      "logit": 2,
      "confidence": 0.9
    },
    {
      "description": "Rhinovirus is stable at ~24.5% (second place), predominantly affecting 5-14 year olds. Historically declines as winter deepens. Not a plausible contender for first place.",
      "supports": "Rhinovirus (Rinov\u00edrus)",
      "logit": -1,
      "confidence": 0.8
    },
    {
      "description": "Influenza A at 20.7% and declining as a SHARE (22.4% \u2192 21.9% \u2192 20.7%) even though absolute cases are rising. Seasonally peaks EW 24-28, but would need to more than double its share to overtake RSV - extremely unlikely in 1-2 weeks.",
      "supports": "Influenza A",
      "logit": -0.5,
      "confidence": 0.75
    },
    {
      "description": "All other viruses (Influenza B at 5.7%, SARS-CoV-2 at 2.0%) are far too low to be contenders. Combined they're under 8%.",
      "supports": "Any other virus (Influenza B, SARS-CoV-2, or other)",
      "logit": -3,
      "confidence": 0.95
    }
  ],
  "tentative_estimate": {
    "probabilities": {
      "Rhinovirus (Rinov\u00edrus)": 0.03,
      "Influenza A": 0.04,
      "VSR (RSV)": 0.92,
      "Any other virus (Influenza B, SARS-CoV-2, or other)": 0.01
    }
  },
  "assessment": "The SE 22 bulletin PDF (the actual resolution source) unambiguously confirms RSV at 49.6% in the 4-week window, nearly double rhinovirus (24.5%) and more than double influenza A (20.7%). \n\nThe question description contains incorrect figures (stating rhinovirus 33.2% and VSR 8.5%), which appear to be either from a different data source, a different time window, or simply erroneous. The resolution criteria explicitly references the \"\u00faltimas 4 semanas\" virus distribution from the InfoGripe bulletin, which I've now verified directly from the PDF.\n\nThe target bulletin will be published on or before June 25 - likely SE 23 (around June 18) or SE 24 (around June 25). Given:\n1. RSV's 25+ percentage point lead over the second-place virus\n2. The 4-week rolling average creating massive inertia\n3. RSV's continued upward trend\n4. RSV still being reported as increasing in most regions\n\nIt is near-certain that RSV will remain the dominant virus in the next bulletin. The only scenario where RSV loses its lead would require an unprecedented, sudden collapse in RSV cases combined with an explosive surge in another virus - something with no historical precedent at this stage of the season.\n\nInfluenza A is the main rising virus seasonally and could eventually overtake RSV later in the winter (EW 26-30), but not within the 1-2 week timeframe of this question. Rhinovirus is stable and declining seasonally.",
  "anchor": "RSV at 49.6% in the most recent 4-week window (SE 22), with a strong upward trend and ~25pp lead over second place",
  "calibration_notes": "The implied probability from factors (>99% RSV) is even higher than my tentative 92%. I'm keeping some probability mass on alternatives to account for: (1) the possibility that I'm misunderstanding which numbers the resolution will use, given the question description's different figures, (2) an unexpected data revision or correction, (3) the seasonal transition potentially being faster than expected. However, the direct verification from the PDF makes me confident that the 4-week window figures are correct.",
  "key_uncertainties": "1. Could the question author's stated figures (rhinovirus 33.2%, VSR 8.5%) reflect a different interpretation of the bulletin that I'm missing? I've verified from the PDF that the 4-week window clearly shows RSV at 49.6%, but the discrepancy is puzzling.\n2. Could a new bulletin published before June 25 show dramatically different figures due to data revisions?",
  "tool_audit": "research() was excellent - retrieved data from 3 consecutive bulletins. fetch_url confirmed the data from the Fiocruz page. The PDF of the SE 22 bulletin was the most critical source, directly confirming the 4-week window figures. The discrepancy with the question description was the main challenge, but primary source verification resolved it clearly.",
  "process_reflection": "The process worked very well for this question. The research tool pulled comprehensive data, and the ability to download and read the actual PDF was critical for resolving the discrepancy between the question description and the actual data. The main friction was the question description containing what appear to be incorrect figures, which initially caused confusion about which metric the resolution would use."
}
```

### 📋 Result

```
{"factor_count": 6, "factor_sum": 1.9, "neutral_factor_count": 0, "factor_breakdown": [{"description": "RSV (VSR) is confirmed at 49.6% of positive SRAG cases in the 4-week window (SE 22 bulletin PDF,
page 3), nearly double the second-place rhinovirus at 24.5%. This is a massive, confirmed lead from the primary resolution source.", "supports": "VSR (RSV)", "logit": 3.0, "confidence": 0.95,
"effective_logit": 2.8499999999999996}, {"description": "RSV trend is upward: 47.6% (SE 20) \u2192 48.5% (SE 21) \u2192 49.6% (SE 22). RSV is still actively rising, driven by ongoing increases in
Nordeste, Sudeste, and Sul regions.", "supports": "VSR (RSV)", "logit": 1.5, "confidence": 0.85, "effective_logit": 1.275}, {"description": "The rolling 4-week window creates enormous inertia. Even if
RSV peaked at SE 22, the 4-week average would only decline gradually. To lose its lead, RSV would need to drop from ~50% to below ~25% in 1-2 weeks - mathematically impossible with a rolling
average.", "supports": "VSR (RSV)", "logit": 2.0, "confidence": 0.9, "effective_logit": 1.8}, {"description": "Rhinovirus is stable at ~24.5% (second place), predominantly affecting 5-14 year olds.
Historically declines as winter deepens. Not a plausible contender for first place.", "supports": "Rhinovirus (Rinov\u00edrus)", "logit": -1.0, "confidence": 0.8, "effective_logit": -0.8},
{"description": "Influenza A at 20.7% and declining as a SHARE (22.4% \u2192 21.9% \u2192 20.7%) even though absolute cases are rising. Seasonally peaks EW 24-28, but would need to more than double
its share to overtake RSV - extremely unlikely in 1-2 weeks.", "supports": "Influenza A", "logit": -0.5, "confidence": 0.75, "effective_logit": -0.375}, {"description": "All other viruses (Influenza B
at 5.7%, SARS-CoV-2 at 2.0%) are far too low to be contenders. Combined they're under 8%.", "supports": "Any other virus (Influenza B, SARS-CoV-2, or other)", "logit": -3.0, "confidence": 0.95,
"effective_logit": -2.8499999999999996}], "dominant_factor": "RSV (VSR) is confirmed at 49.6% of positive SRAG cases in the 4-week window (SE 22 bulletin PDF, page 3), nearly double the second-place
rhinovirus at 24.5%. This is a massive, confirmed lead from the primary resolution source.", "dominant_effective_logit": 2.8499999999999996, "outcome_breakdown": [{"outcome": "VSR (RSV)",
"factor_count": 3, "logit_sum": 5.925, "factors": [{"description": "RSV (VSR) is confirmed at 49.6% of positive SRAG cases in the 4-week window (SE 22 bulletin PDF, page 3), nearly double the second-
place rhinovirus at 24.5%. This is a massive, confirmed lead from the primary resolution source.", "supports": "VSR (RSV)", "logit": 3.0, "confidence": 0.95, "effective_logit": 2.8499999999999996},
{"description": "RSV trend is upward: 47.6% (SE 20) \u2192 48.5% (SE 21) \u2192 49.6% (SE 22). RSV is still actively rising, driven by ongoing increases in Nordeste, Sudeste, and Sul regions.",
"supports": "VSR (RSV)", "logit": 1.5, "confidence": 0.85, "effective_logit": 1.275}, {"description": "The rolling 4-week window creates enormous inertia. Even if RSV peaked at SE 22, the 4-week
average would only decline gradually. To lose its lead, RSV would need to drop from ~50% to below ~25% in 1-2 weeks - mathematically impossible with a rolling average.", "supports": "VSR (RSV)",
"logit": 2.0, "confidence": 0.9, "effective_logit": 1.8}]}, {"outcome": "Rhinovirus (Rinov\u00edrus)", "factor_count": 1, "logit_sum": -0.8, "factors": [{"description": "Rhinovirus is stable at ~24.5%
(second place), predominantly affecting 5-14 year olds. Historically declines as winter deepens. Not a plausible contender for first place.", "supports": "Rhinovirus (Rinov\u00edrus)", "logit": -1.0,
"confidence": 0.8, "effective_logit": -0.8}]}, {"outcome": "Influenza A", "factor_count": 1, "logit_sum": -0.375, "factors": [{"description": "Influenza A at 20.7% and declining as a SHARE (22.4%
\u2192 21.9% \u2192 20.7%) even though absolute cases are rising. Seasonally peaks EW 24-28, but would need to more than double its share to overtake RSV - extremely unlikely in 1-2 weeks.",
"supports": "Influenza A", "logit": -0.5, "confidence": 0.75, "effective_logit": -0.375}]}, {"outcome": "Any other virus (Influenza B, SARS-CoV-2, or other)", "factor_count": 1, "logit_sum":
-2.8499999999999996, "factors": [{"description": "All other viruses (Influenza B at 5.7%, SARS-CoV-2 at 2.0%) are far too low to be contenders. Combined they're under 8%.", "supports": "Any other
virus (Influenza B, SARS-CoV-2, or other)", "logit": -3.0, "confidence": 0.95, "effective_logit": -2.8499999999999996}]}], "mc_distribution_metrics": {"implied_probabilities": {"Influenza A":
0.0018304630842623077, "Any other virus (Influenza B, SARS-CoV-2, or other)": 0.0001540572467271351, "VSR (RSV)": 0.9968187782117242, "Rhinovirus (Rinov\u00edrus)": 0.0011967014572862866},
"tentative_probabilities": {"Rhinovirus (Rinov\u00edrus)": 0.03, "Influenza A": 0.04, "VSR (RSV)": 0.92, "Any other virus (Influenza B, SARS-CoV-2, or other)": 0.01}, "per_option_gap_pp": {"Influenza
A": 3.816953691573769, "Any other virus (Influenza B, SARS-CoV-2, or other)": 0.9845942753272866, "VSR (RSV)": -7.681877821172412, "Rhinovirus (Rinov\u00edrus)": 2.880329854271371}, "max_gap_pp":
-7.681877821172412, "max_gap_option": "VSR (RSV)"}, "sources": ["[(Metaculus) In the InfoGripe bulletin published on or immediately before June 25, 2026, which respiratory virus will be the single
most prevalent among positive SRAG cases nationally over the most recent 4-week window?](https://www.metaculus.com/questions/44052)", "[InfoGripe: cresce n\u00famero de hospitaliza\u00e7\u00f5es por
VSR e influenza A e B](https://agencia.fiocruz.br/infogripe-cresce-numero-de-hospitalizacoes-por-vsr-e-influenza-e-b)", "[InfoGripe: Rio de Janeiro mant\u00e9m curva de crescimento de Covid-19 entre
idosos](https://agencia.fiocruz.br/infogripe)", "[agencia.fiocruz.br](https://agencia.fiocruz.br/sites/agencia.fiocruz.br/files/Resumo_InfoGripe_2026_22.pdf)"]}
```

## 💬 Response

Now let me run the premortem review.

## 🔧 Tool: mcp__premortem__premortem


```json
{
  "counterargument": "The strongest case against RSV winning: The question description explicitly states \"rhinovirus 33.2%, influenza A 20.5%, VSR 8.5%\" as the 4-week window figures from the SE 22 bulletin. If the question author was looking at a DIFFERENT data view or interpretation of \"positive cases\" (e.g., excluding children under 2, or using a different virus categorization), then my reading of the bulletin might not match how the question resolves. The question author may have been looking at a specific subset of the data, or the Ag\u00eancia Fiocruz de Not\u00edcias summary page might present the data differently than the PDF bulletin. Additionally, if the question author interprets \"positive cases\" to include only adult cases (where influenza A and rhinovirus dominate rather than RSV), the resolution could favor rhinovirus. However, this counterargument is weak because: (1) the resolution criteria clearly references the \"\u00faltimas 4 semanas\" / \"preval\u00eancia entre casos positivos\" which matches exactly what the bulletin reports, and (2) the PDF explicitly states RSV at 49.6% for this metric.",
  "what_would_change_my_mind": "1. If a new SE 23 bulletin published before June 25 showed dramatically different figures - e.g., if data revisions for prior weeks shifted the 4-week window virus distribution significantly (RSV dropping below 30% and rhinovirus rising above it). 2. If I discovered that the Ag\u00eancia Fiocruz de Not\u00edcias web page presents a different set of numbers than the PDF bulletin, and the question author was referencing those web page figures rather than the PDF. 3. If the question description's figures (rhinovirus 33.2%, VSR 8.5%) turned out to reflect the correct 4-week window data and my PDF reading was somehow wrong - though I've triple-checked and this is clearly not the case.",
  "confidence_in_estimate": 0.82
}
```

### 📋 Result

```
{"verdict": "approve", "assessment": "## Checks Performed\n\n### Hallucinated Evidence\nAll six factors were verified against the research trace:\n- **Factor 1** (RSV at 49.6%): Confirmed by fetch_url
of the SE 22 Fiocruz page, which returned \"RSV/VSR: 49.6%\" for the 4-week window. The PDF was also downloaded and read, with the trace showing the exact Portuguese text: \"49,6% de v\u00edrus
sincicial respirat\u00f3rio.\"\n- **Factor 2** (RSV trend 47.6% \u2192 48.5% \u2192 49.6%): The research tool retrieved data from three consecutive bulletins (SE 20, 21, 22) confirming these exact
figures.\n- **Factor 4** (Rhinovirus at ~24.5%): Confirmed across all three bulletins in the research output.\n- **Factor 5** (Influenza A at 20.7%, declining share 22.4% \u2192 21.9% \u2192 20.7%):
Confirmed in the trend analysis table in the research output.\n- **Factor 6** (Influenza B 5.7%, SARS-CoV-2 2.0%): Confirmed in the SE 22 bulletin data.\n\nNo hallucinated claims found.\n\n### Double-
Counting\nFactors 1 (current RSV level), 2 (RSV trend), and 3 (rolling-window inertia) all support VSR and draw from the same bulletin data. However, they make distinct arguments: Factor 1 is the
current snapshot, Factor 2 is the trajectory, and Factor 3 is a mathematical argument about how rolling averages work. The overlap is mild and doesn't distort the forecast.\n\n### Wrong-Direction
Factors\nAll logit signs are correct. Factors 1-3 are positive for VSR (RSV). Factors 4-6 are negative for their respective categories (Rhinovirus, Influenza A, other viruses). No issues.\n\n###
Contradictory Assessment\nThe assessment is fully consistent with the factors: RSV dominant at ~50%, rhinovirus distant second at ~25%, influenza A third at ~21%, others negligible.\n\n### Resolution
Criteria\nResolution criteria were fetched via get_metaculus_questions and are present. The criteria specify: \"the single respiratory virus with the highest reported prevalence (percentage) among
laboratory-positive SRAG cases over the most recent four epidemiological weeks.\" The agent correctly engaged with this exact metric from the primary source.\n\n### Resolution Misalignment \u2014 Key
Discrepancy\nThe question description states \"rhinovirus 33.2%, influenza A 20.5%, VSR 8.5%\" for the SE 22 bulletin, but the agent's direct verification of the same bulletin shows RSV at 49.6%,
rhinovirus at 24.5%. The agent explicitly addresses this discrepancy, argues the question description is wrong, and provides strong evidence: (1) the Fiocruz news page confirms RSV 49.6%, (2) the
downloaded PDF confirms the same, (3) three consecutive bulletins show a consistent RSV-dominant trend. The question's \"rhinovirus 33.2%\" is close to the YTD cumulative figure (32.5%), suggesting
the question author may have confused YTD and 4-week figures. The resolution criteria clearly specify the 4-week window, and the agent verified the correct metric from the primary source.\n\n###
Counterargument Quality\nThe counterargument raises the legitimate concern that the question author might be looking at different data views (e.g., excluding children under 2, or adult-only cases).
The agent then dismisses it by noting the resolution criteria explicitly references \"preval\u00eancia entre casos positivos\" which matches the bulletin's reporting. The agent also fetched both the
news page and the PDF and got consistent results. The counterargument is adequate \u2014 not a token gesture.\n\n### Probability Assessment\nWith RSV at 49.6% and a 25pp lead, upward trend, and
rolling-window inertia (the question resolves on a bulletin published ~10 days from now), 92% for VSR is reasonable. The remaining 8% appropriately accounts for uncertainty about the data discrepancy
with the question description and the possibility that a new bulletin could show surprising shifts. I'd estimate 88-92% myself \u2014 the agent's 92% is within a reasonable range and not meaningfully
different from my independent assessment.\n\n### Tool Audit\nAgent claims: \"research() was excellent - retrieved data from 3 consecutive bulletins. fetch_url confirmed the data from the Fiocruz
page.\" Ground truth: 1 research call (0 errors), 3 fetch_url calls (0 errors), 2 web_search calls (0 errors), 9 total calls with 0% error rate. The audit is accurate.\n\n### Worldview
Consistency\nThe worldview research entry (infogripe-fiocruz-bulletin-june-2026-respiratory-v-fa5773be) confirms RSV at 49.6% for the 4-week window, consistent with all factors. No contradicting
worldview entries found. No worldview forecasts directory exists for cross-question consistency checks."}
```

## 💬 Response

The premortem reviewer approved the forecast. Now I can submit the final structured output.

## 🔧 Tool: StructuredOutput


```json
{
  "summary": "RSV (VSR) is overwhelmingly the most prevalent virus in the InfoGripe 4-week window, confirmed at 49.6% of positive SRAG cases in the most recent bulletin (SE 22, published June 11, 2026). This is nearly double the second-place rhinovirus (24.5%) and more than double influenza A (20.7%). RSV has been trending upward (47.6% \u2192 48.5% \u2192 49.6% over SE 20-22) and is still increasing in most Brazilian regions. The rolling 4-week window creates massive inertia, making it mathematically impossible for RSV to lose its lead in the 1-2 weeks before the target bulletin. Note: the question description contains incorrect figures (rhinovirus 33.2%, VSR 8.5%) that appear to confuse YTD cumulative figures with the 4-week window; the actual bulletin PDF and Fiocruz news page both confirm RSV at 49.6% for the 4-week window, which is the metric specified in the resolution criteria.",
  "anchor": "RSV at 49.6% in the most recent 4-week window (SE 22 bulletin), with a ~25 percentage point lead over second place and an upward trend. This is the direct resolution source.",
  "factors": [
    {
      "description": "RSV (VSR) confirmed at 49.6% of positive SRAG cases in the 4-week window (SE 22 bulletin PDF, page 3), nearly double rhinovirus at 24.5%. Verified from the primary resolution source.",
      "supports": "VSR (RSV)",
      "logit": 3,
      "confidence": 0.95
    },
    {
      "description": "RSV trend is upward: 47.6% (SE 20) \u2192 48.5% (SE 21) \u2192 49.6% (SE 22). RSV is still actively rising across most regions.",
      "supports": "VSR (RSV)",
      "logit": 1.5,
      "confidence": 0.85
    },
    {
      "description": "Rolling 4-week window creates massive inertia. RSV would need to drop from ~50% to below ~25% in 1-2 weeks to lose its lead - mathematically impossible with a rolling average.",
      "supports": "VSR (RSV)",
      "logit": 2,
      "confidence": 0.9
    },
    {
      "description": "Rhinovirus is stable at ~24.5% (second place), predominantly affecting 5-14 year olds. Historically declines as winter deepens.",
      "supports": "Rhinovirus (Rinov\u00edrus)",
      "logit": -1,
      "confidence": 0.8
    },
    {
      "description": "Influenza A at 20.7% and declining as a share despite absolute cases rising. Would need to more than double to overtake RSV in 1-2 weeks.",
      "supports": "Influenza A",
      "logit": -0.5,
      "confidence": 0.75
    },
    {
      "description": "All other viruses far too low to contend: Influenza B at 5.7%, SARS-CoV-2 at 2.0%.",
      "supports": "Any other virus (Influenza B, SARS-CoV-2, or other)",
      "logit": -3,
      "confidence": 0.95
    }
  ],
  "probabilities": {
    "Rhinovirus (Rinov\u00edrus)": 0.03,
    "Influenza A": 0.04,
    "VSR (RSV)": 0.92,
    "Any other virus (Influenza B, SARS-CoV-2, or other)": 0.01
  }
}
```

### 📋 Result

```
Structured output provided successfully
```

## 💬 Response

## Forecast Summary

**Question:** Which respiratory virus will be most prevalent in the InfoGripe bulletin published on or before June 25, 2026?

### Key Finding
The actual SE 22 bulletin (published June 11, 2026) — verified via both the Fiocruz news page and the downloaded PDF — shows **RSV (VSR) at 49.6%** of positive SRAG cases in the 4-week window, far ahead of rhinovirus (24.5%) and influenza A (20.7%).

> ⚠️ **Important discrepancy:** The question description states "rhinovirus 33.2%, VSR 8.5%" but these appear to be incorrect — likely confusing YTD cumulative figures with the 4-week window. The resolution criteria explicitly specify the 4-week window metric.

### Final Probabilities
| Option | Probability |
|--------|------------|
| **VSR (RSV)** | **92%** |
| Influenza A | 4% |
| Rhinovirus | 3% |
| Any other virus | 1% |

### Rationale
- RSV holds a **25+ percentage point lead** over the second-place virus
- RSV is **still trending upward** (47.6% → 48.5% → 49.6% over 3 weeks)
- The **rolling 4-week window** makes it mathematically impossible for RSV to lose its lead in 1-2 bulletins
- Small residual probability accounts for uncertainty about how the question author interprets the data, given the discrepancy in the question description
